Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation,
AUTOR(ES)
Komnitski, Melpone; Komnitski, Angelo; Komnitski Junior, Amilton; Castro, Caio César Silva de
FONTE
An. Bras. Dermatol.
DATA DE PUBLICAÇÃO
2020-08
RESUMO
Abstract Vitiligo is a disease that causes macules and achromic and/or hypochromic patches, which can affect from small areas to the entire tegument. Treatment options are few and are generally ineffective. Recently, some case reports have appeared which show positive results with the use of Janus kinase inhibitors associated with phototherapy. This report details the case of a patient with rheumatoid arthritis associated with vitiligo in treatment for two years, whose condition partially improved initially after eight months of oral tofacitinib at a dose of 5 mg twice a day, without exposure to ultraviolet radiation and with continuous improvement during these two years of treatment.
Documentos Relacionados
- Isolation of radiation-resistant bacteria without exposure to irradiation.
- Occupational hazards in hospitals: accidents, radiation, exposure to noxious chemicals, drug addiction and psychic problems, and assault.
- Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib—a biological or synthetic target specific) in patients hospitalized with COVID-19
- Developmental effects of additional ultraviolet a radiation, growth regulators and tyrosine in Alternanthera brasiliana (L.) Kuntze cultured in vitro
- Ultraviolet radiation, but not γ radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389
